Key result
Adenoviral cardiac gene transfer with hypothermia achieves ~77% transfection efficiency and slows LV dysfunction progression.
BACKGROUND: One of the most important problems in developing in vivo cardiac gene transfer has been low transfection efficiency. A novel in vivo technique was developed, tested in normal hamsters, and the feasibility of restoring a deficient structural protein (delta-sarcoglycan) in the cardiomyopathic (CM) hamster evaluated. METHODS AND RESULTS: Adenoviral (AdV) vectors encoding either the lacZ gene or delta-sarcoglycan gene were constructed. Hypothermia was achieved in hamsters by external body cooling to a rectal temperature of 18 to 25 degrees C. Through a small thoracotomy, the ascending aorta and the main pulmonary artery were occluded with snares, and cardioplegic solution containing histamine was injected into the aortic root; viral constructs were delivered 3 to 5 minutes later followed by release of the occluders and rewarming. Four days later, homogeneous beta-galactosidase expression was detected throughout the ventricles of the normal hearts (average 77.3+/-9.0% [SEM] of left ventricular myocytes). At 1 and 3 weeks after transfection, immunostaining showed extensive restoration of delta-sarcoglycan as well as alpha- and beta-sarcoglycan proteins to the myocyte membranes, despite loss of beta-galactosidase expression at 3 weeks. Also, at 3 weeks after gene transfer, there was significantly less progression of left ventricular dysfunction assessed as percent change in fractional shortening compared with controls. CONCLUSIONS: This study demonstrates the feasibility of high efficiency in vivo myocardial gene transfer and shows application in improving the level of a deficient cardiac structural protein and cardiac function in CM hamsters. The approach should be useful for assessing effects of expressing other genes that influence the structure or function of the normal and failing heart.
No takes yet. Share an insight, caveat, or question.
Ikeda et al. (2002) studied Cardiomyopathy. Adenoviral vectors encoding delta-sarcoglycan delivered via in vivo cardiac gene transfer vs. Controls was evaluated on Transfection efficiency (percent of left ventricular myocytes expressing beta-galactosidase). In vivo cardiac gene transfer using adenoviral vectors and hypothermia achieved 77.3% transfection efficiency and significantly reduced the progression of left ventricular dysfunction in CM hamsters.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: